<DOC>
	<DOC>NCT01755078</DOC>
	<brief_summary>The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.</brief_summary>
	<brief_title>Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Males or females aged between 1870 years old Subject with hyperphosphatemia (5.5 8.5 mg/dL) at both WK(2) and WK0 On stable TIW hemodialysis for 3 months or longer Patients with hypercalcemia (corrected serum calcium &gt; 10.5 mg/dL) Any of the following abnormalities: ALT or AST &gt; 3X ULN; iPTH &gt; 1000 or &lt; 150 pg/mL History of dysphagia or swallowing disorders History of GI motility disorder or GI bleeding within 3 months prior to entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phosphate binder</keyword>
</DOC>